NCT01345253 - GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia | Biotech Hunter

Enrollment

709

Participants

Timeline

Start Date

May 23, 2011

Primary Completion Date

September 15, 2015

Study Completion Date

September 21, 2018

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

Belimumab

10mg/kg administered intravenously. Dosing at Weeks 0, 2, and 4, then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.

DRUG

Placebo

Administered intravenously. Dosing at Weeks 0, 2, and 4, and then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.

Trial Locations (47)

100029

GSK Investigational Site, Beijing

100032

GSK Investigational Site, Beijing

100044

GSK Investigational Site, Beijing

150001

GSK Investigational Site, Harbin

200001

GSK Investigational Site, Shanghai

200003

GSK Investigational Site, Shanghai

200025

GSK Investigational Site, Shanghai

200433

GSK Investigational Site, Shanghai

210029

GSK Investigational Site, Nanjing

215006

GSK Investigational Site, Suzhou

230001

GSK Investigational Site, Hefei

250012

GSK Investigational Site, Jinan

300052

GSK Investigational Site, Tianjin

310009

GSK Investigational Site, Hangzhou

400038

GSK Investigational Site, Chongqing

410008

GSK Investigational Site, Changsha

410011

GSK Investigational Site, Changsha

510080

GSK Investigational Site, Guangzhou

510260

GSK Investigational Site, Guangzhou

510630

GSK Investigational Site, Guangzhou

610041

GSK Investigational Site, Chengdu

650101

GSK Investigational Site, Kunming

710032

GSK Investigational Site, Xi'an

275-8580

GSK Investigational Site, Chiba

791-0295

GSK Investigational Site, Ehime

807-8555

GSK Investigational Site, Fukuoka

810-8563

GSK Investigational Site, Fukuoka

730-8619

GSK Investigational Site, Hiroshima

739-0002

GSK Investigational Site, Hiroshima

060-8604

GSK Investigational Site, Hokkaido

060-8648

GSK Investigational Site, Hokkaido

675-8545

GSK Investigational Site, Hyōgo

980-8574

GSK Investigational Site, Miyagi

852-8501

GSK Investigational Site, Nagasaki

857-1195

GSK Investigational Site, Nagasaki

710-0824

GSK Investigational Site, Okayama

901-0243

GSK Investigational Site, Okinawa

321-0293

GSK Investigational Site, Tochigi

113-8431

GSK Investigational Site, Tokyo

Unknown

GSK Investigational Site, Busan

GSK Investigational Site, Seoul

700-721

GSK Investigational Site, Daegu

400-711

GSK Investigational Site, Incheon

110-744

GSK Investigational Site, Seoul

133-792

GSK Investigational Site, Seoul

137-701

GSK Investigational Site, Seoul

443-721

GSK Investigational Site, Suwon, Kyonggi-do